Gensia Automedics Inc., Gensia deal

GNSA transferred its medical products, including GenESA System, Feedback Controlled Heparin System and Brevibloc esmolol, a short-acting beta blocker, to its Automedics subsidiary. GNSA will receive milestones, royalties, and manufacturing payments. GNSA will incur a charge of $10 million for the fourth quarter of 1997, which includes $7 million in prepaid royalties and capitalized milestone payments. ...